18:55 , Mar 17, 2017 |  BC Week In Review  |  Company News

argenx, Staten Biotechnology deal

Staten exercised an option under a 2015 deal to license ARGX-116 from argenx. Staten is responsible for ongoing development of the preclinical dyslipidemia candidate, and argenx is eligible for a "double-digit portion on income related...